Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
Sean J PittockMichael BarnettJeffrey L BennettAchim BertheleJérôme de SezeMichael LevyIchiro NakashimaCelia Oreja-GuevaraJacqueline PalaceFriedemann PaulCarlo PozzilliMarcus YountzKerstin AllenYasmin MashhoonJae-Won HyunPublished in: Annals of neurology (2023)
Ravulizumab significantly reduced relapse risk in patients with AQP4+ NMOSD, with a safety profile consistent with those of eculizumab and ravulizumab across all approved indications. This article is protected by copyright. All rights reserved.
Keyphrases